252 related articles for article (PubMed ID: 21829177)
1. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.
Suk JS; Boylan NJ; Trehan K; Tang BC; Schneider CS; Lin JM; Boyle MP; Zeitlin PL; Lai SK; Cooper MJ; Hanes J
Mol Ther; 2011 Nov; 19(11):1981-9. PubMed ID: 21829177
[TBL] [Abstract][Full Text] [Related]
2. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
[TBL] [Abstract][Full Text] [Related]
3. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
4. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
5. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.
Suk JS; Kim AJ; Trehan K; Schneider CS; Cebotaru L; Woodward OM; Boylan NJ; Boyle MP; Lai SK; Guggino WB; Hanes J
J Control Release; 2014 Mar; 178():8-17. PubMed ID: 24440664
[TBL] [Abstract][Full Text] [Related]
6. Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation.
Boylan NJ; Suk JS; Lai SK; Jelinek R; Boyle MP; Cooper MJ; Hanes J
J Control Release; 2012 Jan; 157(1):72-9. PubMed ID: 21903145
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly-L-lysine.
Boylan NJ; Kim AJ; Suk JS; Adstamongkonkul P; Simons BW; Lai SK; Cooper MJ; Hanes J
Biomaterials; 2012 Mar; 33(7):2361-71. PubMed ID: 22182747
[TBL] [Abstract][Full Text] [Related]
8. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
Dasgupta B; King M
Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
[TBL] [Abstract][Full Text] [Related]
9. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
10. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro.
Stern M; Caplen NJ; Browning JE; Griesenbach U; Sorgi F; Huang L; Gruenert DC; Marriot C; Crystal RG; Geddes DM; Alton EW
Gene Ther; 1998 Jan; 5(1):91-8. PubMed ID: 9536269
[TBL] [Abstract][Full Text] [Related]
11. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels.
Yuan S; Hollinger M; Lachowicz-Scroggins ME; Kerr SC; Dunican EM; Daniel BM; Ghosh S; Erzurum SC; Willard B; Hazen SL; Huang X; Carrington SD; Oscarson S; Fahy JV
Sci Transl Med; 2015 Feb; 7(276):276ra27. PubMed ID: 25717100
[TBL] [Abstract][Full Text] [Related]
12. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine.
De Lisle RC; Roach E; Jansson K
Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G577-84. PubMed ID: 17615175
[TBL] [Abstract][Full Text] [Related]
13. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.
Hida K; Lai SK; Suk JS; Won SY; Boyle MP; Hanes J
PLoS One; 2011; 6(5):e19919. PubMed ID: 21637751
[TBL] [Abstract][Full Text] [Related]
14. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
[TBL] [Abstract][Full Text] [Related]
15. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
Addante A; Raymond W; Gitlin I; Charbit A; Orain X; Scheffler AW; Kuppe A; Duerr J; Daniltchenko M; Drescher M; Graeber SY; Healy AM; Oscarson S; Fahy JV; Mall MA
Eur Respir J; 2023 May; 61(5):. PubMed ID: 37080569
[TBL] [Abstract][Full Text] [Related]
16. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors.
Schuster BS; Kim AJ; Kays JC; Kanzawa MM; Guggino WB; Boyle MP; Rowe SM; Muzyczka N; Suk JS; Hanes J
Mol Ther; 2014 Aug; 22(8):1484-1493. PubMed ID: 24869933
[TBL] [Abstract][Full Text] [Related]
17. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
Ehre C; Rushton ZL; Wang B; Hothem LN; Morrison CB; Fontana NC; Markovetz MR; Delion MF; Kato T; Villalon D; Thelin WR; Esther CR; Hill DB; Grubb BR; Livraghi-Butrico A; Donaldson SH; Boucher RC
Am J Respir Crit Care Med; 2019 Jan; 199(2):171-180. PubMed ID: 30212240
[TBL] [Abstract][Full Text] [Related]
18. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
Dasgupta B; Brown NE; King M
Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro.
Dasgupta B; Tomkiewicz RP; Boyd WA; Brown NE; King M
Pediatr Pulmonol; 1995 Aug; 20(2):78-82. PubMed ID: 8570306
[TBL] [Abstract][Full Text] [Related]
20. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
